In its non-precedential decision in INO Therapeutics LLC v. Praxair Distribution
Inc., the Federal Circuit agreed with the
district court that method of treatment claims reciting
“excluding” specific patients from treatment were
ineligible for patenting under 35 USC § 101. Stakeholders in
the personalized medicine space likely are hoping that this
decision will be cabined to the specific claims at issue, and not
herald new scrutiny of more typical personalized medicine
claims.
The INOMax® Patents At Issue
The underlying ANDA litigation involved a number of Orange
Book-listed patents for INOMax®, including U.S. Patent No.
8,282,966, U.S. Patent No. 8,293,284, U.S. Patent No. 8,795,741,
U.S. Patent No. 8,431,163, and U.S. Patent No. 8,846,112.
INOMax® is a nitric oxide delivery system indicated for use to
improve oxygenation and reduce the need for extracorporeal membrane
oxygenation in neonatal patients with hypoxic respiratory failure
associated with clinical or